GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.

Overview of attention for article published in Diabetes Care, November 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 67 news outlets
blogs: 5 blogs
twitter: 262 X users
patent: 1 patent
facebook: 3 Facebook pages

wikipedia: 7 Wikipedia pages
reddit: 60 Redditors
video: 3 YouTube creators
bluesky: 4 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 208 Mendeley

So far, Altmetric has seen 94 news stories from 67 outlets.

Ozempic pourrait-il augmenter le risque de cancer de la thyroïde ? Une étude française alerte

Science & Vie, 10 Aug 2026

[Cet article a initialement été publié le 13 août 2025] La lutte contre l’obésité connaît depuis quelques années une révolution…

TikTok’s fave weight loss drugs: Link to thyroid cancer?

Pediatric News , 17 Jul 2026

Using GLP-1 receptor agonists for obesity We have extensive prior experience with glucagon-like peptide 1 (GLP-1) receptor…

GLP-1 drugs – how real are the risks?

Medical Brief, 22 Apr 2026

The expanding use of GLP-1 receptor agonists (RAs) requires careful evaluation of efficacy, tolerability, and safety across…

Farmaci GLP-1 sotto esame: quanto sono reali i rischi?

CronachediScienza.it, 20 Apr 2026

Il loro uso in espansione richiede un’attenta valutazione dell’efficacia, tollerabilità e sicurezza in popolazioni diverse…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 90 additional news stories.